^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Erythropoiesis stimulating agent

    Related drugs:
    2d
    DarbeLus: Luspatercept + Darbepoetin in MDS (clinicaltrials.gov)
    P2, N=60, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Reblozyl (luspatercept-aamt) • Aranesp (darbepoetin alfa)
    4d
    A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects (clinicaltrials.gov)
    P1, N=68, Completed, Longbio Pharma | Active, not recruiting --> Completed
    Trial completion
    21d
    DIVI: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (clinicaltrials.gov)
    P2, N=120, Recruiting, University of Washington | Trial completion date: Dec 2027 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Aranesp (darbepoetin alfa)
    3ms
    CORRECTION: Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (clinicaltrials.gov)
    P3, N=0, Withdrawn, Akebia Therapeutics | N=71 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    3ms
    CONVERSION: Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease (clinicaltrials.gov)
    P3, N=0, Withdrawn, Akebia Therapeutics | N=71 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    3ms
    Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study (clinicaltrials.gov)
    P4, N=40, Active, not recruiting, Gangnam Severance Hospital | N=77 --> 40
    Enrollment change
    |
    Aranesp (darbepoetin alfa)
    3ms
    Transcriptional dynamics of the oligodendrocyte lineage and its regulation by the brain erythropoietin system. (PubMed, Nat Commun)
    Mice lacking EPOR from mature oligodendrocytes show subtle deficiencies of adult myelination in hippocampal fimbria and mild working memory deficits. These gain- and loss-of-function experiments may further suggest EPO as clinically safe treatment for remyelination therapies.
    Journal
    |
    EPO (Erythropoietin)
    4ms
    Knock Out of miRNA-30a-5p and Reconstitution of the Actin Network Dynamics Partly Restores the Impaired Terminal Erythroid Differentiation during Blood Pharming. (PubMed, Stem Cell Rev Rep)
    Previously, we developed imBMEP-A, the first erythroid cell line derived from reticulocyte progenitors, which maintains robust hemoglobin expression and erythroid differentiation in the presence of erythropoietin (EPO) despite its immortalized state...These interventions improved viability, restored actin network formation, and increased terminal erythropoiesis, yielding 22.1 ± 1.7% more orthochromatic erythroblasts. These findings establish a foundation for optimizing imBMEP-A cells for therapeutic use and advancing the understanding the pathophysiology of erythroleukemia.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2L1 (BCL2-like 1) • MIR30A (MicroRNA 30a)
    4ms
    GX-E4-HV-003: Clinical Trial of Efepoetin Alfa in Healthy Subjects (clinicaltrials.gov)
    P1, N=40, Completed, Genexine, Inc. | Recruiting --> Completed | Trial completion date: Oct 2025 --> Mar 2025
    Trial completion • Trial completion date
    4ms
    Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov)
    P3, N=228, Recruiting, Biocad
    New P3 trial
    5ms
    Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Jul 2026
    Trial completion date
    |
    Aranesp (darbepoetin alfa) • Ilaris (canakinumab)
    5ms
    Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=24, Recruiting, Groupe Francophone des Myelodysplasies | Not yet recruiting --> Recruiting
    Enrollment open
    |
    arsenic trioxide • Reblozyl (luspatercept-aamt)